2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Biological Activity
RS-1 is a RAD51 activator, and also increases CRISPR/Cas9-mediated knock-in efficiencies.
In Vitro
RS-1 is a RAD51 activator, stimulating binding of hRAD51 to DNA with Kd ranging from 48 nM to 107 nM in the presence of ATP or ADP and in the absence of a nucleotide cofactor, and such an effect is not via inhibiting its ATPase activity. RS-1 (20 μM) affects the length and helical pitch of hRAD51 protein-DNA complexes. RS-1 (0, 1, 5, 10, 15, 20, and 25 μM) stimulates strand assimilation activity of hRAD51. RS-1 (7.5 μM) promotes resistance of human cells to cross-linking chemotherapy[1]. RS-1 (0, 7.5, 15 μM) increases Cas9-mediated knock-in efficiencies in rabbit embryos[2].
In Vivo
No in vivo data are provided in the current product source. Contact us for further information.
Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.
Adavivint is a potent and selective inhibitor of canonical Wnt signaling, with an EC50 of 19.5 nM via a high-throughput TCF/LEF-reporter assay in SW480 colon cancer cells.
WZ4002 is a mutant selective EGFR inhibitor with IC50s of 2, 8, 3 and 2 nM for EGFRL858R, EGFRL858R/T790M, EGFRE746_A750 and EGFRE746_A750/T790M, respectively.
GW788388 is a potent and selective inhibitor of ALK5 with IC50 of 18 nM, and also inhibits TGF-β type II receptor and activin type II receptor activities, without inhibiting BMP type II receptor.
Fluzoparib (SHR-3162) is a novel, potent and orally available inhibitor of PARP; potently inhibited PARP1 enzyme activity and induced DNA double-strand breaks, G2/M arrest and apoptosis in homologous recombination…
